Pharma only recently suffered in Congress' shutdown-averting spending deal, which put the industry on the hook for bigger discounts in the Medicare Part D coverage gap, but it's acting fast to try to reverse the damage.Original Article
Pharma unleashes lobbying power to fight surprising—and costly—changes to Medicare Part D
